Clinical Trials Logo

Gastric Carcinoma clinical trials

View clinical trials related to Gastric Carcinoma.

Filter by:

NCT ID: NCT02611024 Recruiting - Glioblastoma Clinical Trials

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

Start date: May 6, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

Prospective, open-label, dose-ranging, uncontrolled phase I/II study of Lurbinectedin in combination with irinotecan. The study will be divided into two stages: a Phase I dose escalation stage and a Phase II expansion stage.

NCT ID: NCT02409199 Recruiting - Gastric Carcinoma Clinical Trials

A Study of Apatinib Versus Docetaxol Patients With Advanced Gastric Cancer

Start date: June 2015
Phase: Phase 2/Phase 3
Study type: Interventional

This multicenter, randomized study will evaluate the efficacy and safety of apatinib compared to docetaxel treatment in patients with advanced gastric cancer. At the start of the trial, patients will be randomized to one treatment arm: Arm A: apatinib 850mg qd every 3 weeks; Arm B: docetaxel 60mg/m2 every 3 weeks. Tumor assessment will be done every 8 weeks according to RECIST 1.1. The primary endpoint is progression free survival (PFS).

NCT ID: NCT02317471 Recruiting - Gastric Carcinoma Clinical Trials

Immunotherapy of Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96

Start date: November 2014
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of autologous gp96 treatment of gastric cancer.

NCT ID: NCT01573468 Recruiting - Gastric Carcinoma Clinical Trials

Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer

TESEGAST
Start date: April 2012
Phase: Phase 2
Study type: Interventional

This study is being performed to evaluate the efficacy and safety of capecitabine in combination with tesetaxel versus capecitabine in combination with placebo as second-line treatment for patients with gastric cancer.

NCT ID: NCT01348009 Recruiting - Gastric Carcinoma Clinical Trials

Tesetaxel Plus Capecitabine and Cisplatin in Advanced Gastric Cancer

Start date: May 2011
Phase: Phase 1/Phase 2
Study type: Interventional

Cisplatin, an intravenously administered platinum agent, in combination with an intravenously administered taxane and capecitabine has been shown to improve time to disease progression and overall survival in previously untreated patients with gastric cancer. This study is being performed to evaluate an orally administered taxane (tesetaxel) in combination with cisplatin and capecitabine in previously untreated patients with gastric cancer.

NCT ID: NCT00639522 Recruiting - Gastric Carcinoma Clinical Trials

Dose Escalation Study of Liposomal Paclitaxel With/Without Capecitabine in Patients With Advanced Gastric Carcinoma

Start date: May 2008
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate the maximum tolerated dose and pharmacokinetics of liposomal paclitaxel with/without capecitabine in Chinese cancer patients with advanced gastric carcinoma.